Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
American Society of Clinical Oncology (ASCO)
Online
2021-12-14
DOI
10.1200/jco.21.01935
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
- (2021) Ola Landgren et al. JAMA Oncology
- Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients.
- (2021) Francesca Gay et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
- (2021) Philippe Moreau et al. LANCET ONCOLOGY
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
- (2020) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
- (2020) Peter M Voorhees et al. BLOOD
- Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
- (2020) Jagoda Jasielec et al. BLOOD
- Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma
- (2020) Ibai Goicoechea et al. BLOOD
- International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
- (2020) Luciano J. Costa et al. LEUKEMIA
- A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
- (2020) Nikhil C. Munshi et al. Blood Advances
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma
- (2019) Laura Rosiñol et al. BLOOD
- A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
- (2018) Brian A. Walker et al. LEUKEMIA
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
- (2018) Aurore Perrot et al. BLOOD
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- (2018) L. Rasche et al. LEUKEMIA
- Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
- (2017) Juan-Jose Lahuerta et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
- (2017) Philip L. McCarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of 18 F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
- (2017) Michele Cavo et al. LANCET ONCOLOGY
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- Gene Expression Profiles in Myeloma: Ready for the Real World?
- (2016) Raphael Szalat et al. CLINICAL CANCER RESEARCH
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System
- (2015) R. Kuiper et al. BLOOD
- Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
- (2014) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started